3,560 material Form 8-K filings that 2,489 companies we cover made with the SEC in October 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). 2,508 of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Endovia Health Sciences announced that the FDA's Center for Veterinary Medicine determined CannEpil qualifies as a minor use for controlling bone cancer pain in dogs, making it eligible to pursue the conditional approval pathway. The product remains investigational and is not approved or conditionally approved, and the company has not given revenue or financial figures in this filing.
FDA Center for Veterinary Medicine determined CannEpil qualifies as a minor use under the MUMS program
Endovia and Lupvindol are scheduled to meet the FDA for a Pre-Submission Conference on November 19, 2026
Company is working toward a potential veterinary launch in 2027, subject to FDA approval
Purple Innovation received a Nasdaq letter on September 30, 2026, stating that its Market Value of Publicly Held Shares was below the $15 million minimum for the last 30 consecutive business days. The notice has no immediate effect on the listing or trading of its Class A common stock, but if the company does not regain compliance by the stated Compliance Date, Nasdaq will notify it that its securities are subject to delisting.
Nasdaq notice dated September 30, 2026 cites a $15 million minimum MVPHS requirement under Nasdaq Listing Rules 5450(b)(2)(C) and 5450(b)(3)(C)
To regain compliance, MVPHS must close at $15 million or more for at least ten consecutive business days within the Compliance Period
The filing states the Compliance Date as March 29, 2026, and says the company may appeal a delisting determination to a hearings panel
The company may also consider transferring to the Nasdaq Capital Market if it meets that market's continued listing requirements
Nasdaq's Hearings Panel granted SCWorx's request for reconsideration on October 2, 2026, found the company compliant with continued listing requirements, and approved continued listing on The Nasdaq Capital Market. Trading on Nasdaq, suspended since April 14, 2026, will resume on a date Nasdaq has yet to schedule, and the stock trades on the OTCQB until then. The approval carries a one-year Panel Monitor through October 2, 2027, and the company's private placement investors waived termination rights tied to the earlier delisting decision, though those rights revive if the delisting takes effect.
On October 2, 2026, the Panel granted reconsideration of its September 17, 2026 delisting decision and approved continued listing on The Nasdaq Capital Market
Publicly held shares rose to 549,092 as of September 17, 2026, after the September 16, 2026 private placement of 350,000 shares and related warrants
Nasdaq trading has been suspended since April 14, 2026; the stock stays on the OTCQB under WORX until Nasdaq sets a reinstatement date
If all purchasers terminated their purchases, the company would have to return an aggregate of $938,000 and the placement shares and warrants would be cancelled
Benitec Biopharma said the FDA asked for additional available data, including from the company-sponsored OPMD Natural History Study, as discussions on an open-label, single-arm pivotal study for BB-301 continue. The company said it expects to confirm the final pivotal design in the first quarter of 2027 and that the pivotal study timeline remains on track, with patient enrollment planned to begin in mid-2027.
FDA requested additional available data, including from the Benitec-sponsored OPMD Natural History Study
Final pivotal study design expected to be confirmed in 1Q 2027
Patient enrollment for the BB-301 pivotal study planned to begin in mid-2027
Interim BB-301 Phase 1b/2a results to be presented as a late-breaking poster at ESGCT in Hamburg, October 27-30, 2026
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.